Comprehensive Data For IPF, COPD, Asthma Trials To Be Presented by Boehringer Ingelheim

Representatives from Boehringer Ingelheim will be presenting 18 abstracts containing data from idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), and asthma trials conducted with compounds developed by the company at the European Respiratory Society (ERS) to be held at the end of this week. The rare disease insights and information to be presented underscore the company’s focus on and dedication to addressing unmet needs of patients living with pulmonary fibrosis.

A variety of data will be presented at the meeting, including the first results of phase 3 trials investigating the only fixed-dose combination containing tiotropium for the treatment of COPD and analyses of phase 3 trials evaluating treatments for asthma and idiopathic pulmonary fibrosis.

The studies can be grouped into four categories. Most general are studies evaluating Spiriva® (tiotropium). Topics range from the safety of tiotropium in renally impaired patients to the impact of treatment on mortality and cardiovascular outcomes.

[adrotate group=”3″]

Similarly, another group of studies will discuss the effects of tiotropium Respimat® added to inhaled corticosteroid treatment on asthma patients. Asthma severity, exacerbation risk, and adverse effects are reported metrics. Improvements in symptom control and risk of exacerbations were announced previously.

A third set of studies investigated tiotropium along with olodaterol fixed dose combination delivered via the Respimat® Soft Mist inhaler and compared patients to those treated with only tiotropium or olodaterol alone. These data are pivotal to the recent regulatory submissions in Europe and the United States to allow approval for clinical use. The studies evaluated COPD patients for one year and included the 5,000-patient TONADO phase 3 study and the TIOSPIR study.

Finally, additional data from two phase 3 INPULSIS trials evaluating nintedanib in patients with idiopathic pulmonary fibrosis will cover the results of primary and secondary endpoints. It was previously announced that nintedanib can slow the decline in lung function and the progression in disease of patients.

During the meeting, two media briefings will provide additional information regarding the studies. The original briefing summarized here can be found on Boehringer Ingelheim’s website.